vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与OFG BANCORP（OFG）财务数据对比。点击上方公司名可切换其他公司
OFG BANCORP的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.2倍（$184.3M vs $152.6M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 30.3%，领先4.2%），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs 0.9%），OFG BANCORP自由现金流更多（$199.3M vs $44.9M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 2.8%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
OFG Bancorp成立于1964年，总部位于波多黎各圣胡安，是东方银行的金融控股公司。公司通过东方银行、东方金融服务有限责任公司、东方保险有限责任公司等核心子公司，主要面向波多黎各和美属维尔京群岛市场，提供多元化的零售与商业银行、贷款、财富管理相关产品、服务及技术解决方案。
CPRX vs OFG — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $184.3M |
| 净利润 | $52.7M | $55.9M |
| 毛利率 | 82.9% | — |
| 营业利润率 | 40.5% | 25.7% |
| 净利率 | 34.5% | 30.3% |
| 营收同比 | 7.6% | 0.9% |
| 净利润同比 | -5.8% | 11.0% |
| 每股收益（稀释后） | $0.40 | $1.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $184.3M | ||
| Q3 25 | $148.4M | $186.2M | ||
| Q2 25 | $146.6M | $182.4M | ||
| Q1 25 | $141.4M | $178.6M | ||
| Q4 24 | $141.8M | $182.7M | ||
| Q3 24 | $128.7M | $174.7M | ||
| Q2 24 | $122.7M | $179.8M | ||
| Q1 24 | $98.5M | $174.4M |
| Q4 25 | $52.7M | $55.9M | ||
| Q3 25 | $52.8M | $51.8M | ||
| Q2 25 | $52.1M | $51.8M | ||
| Q1 25 | $56.7M | $45.6M | ||
| Q4 24 | $55.9M | $50.3M | ||
| Q3 24 | $43.9M | $47.0M | ||
| Q2 24 | $40.8M | $51.1M | ||
| Q1 24 | $23.3M | $49.7M |
| Q4 25 | 82.9% | — | ||
| Q3 25 | 84.7% | — | ||
| Q2 25 | 85.9% | — | ||
| Q1 25 | 87.3% | — | ||
| Q4 24 | 84.7% | — | ||
| Q3 24 | 85.0% | — | ||
| Q2 24 | 87.4% | — | ||
| Q1 24 | 87.3% | — |
| Q4 25 | 40.5% | 25.7% | ||
| Q3 25 | 44.7% | 33.0% | ||
| Q2 25 | 45.2% | 36.1% | ||
| Q1 25 | 44.8% | 33.3% | ||
| Q4 24 | 44.3% | 28.9% | ||
| Q3 24 | 39.6% | 35.4% | ||
| Q2 24 | 44.2% | 39.6% | ||
| Q1 24 | 27.5% | 38.9% |
| Q4 25 | 34.5% | 30.3% | ||
| Q3 25 | 35.6% | 27.8% | ||
| Q2 25 | 35.6% | 28.4% | ||
| Q1 25 | 40.1% | 25.5% | ||
| Q4 24 | 39.4% | 27.6% | ||
| Q3 24 | 34.1% | 26.9% | ||
| Q2 24 | 33.2% | 28.4% | ||
| Q1 24 | 23.6% | 28.5% |
| Q4 25 | $0.40 | $1.27 | ||
| Q3 25 | $0.42 | $1.16 | ||
| Q2 25 | $0.41 | $1.15 | ||
| Q1 25 | $0.45 | $1.00 | ||
| Q4 24 | $0.44 | $1.10 | ||
| Q3 24 | $0.35 | $1.00 | ||
| Q2 24 | $0.33 | $1.08 | ||
| Q1 24 | $0.19 | $1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $1.0B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $1.4B |
| 总资产 | $1.1B | $12.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $1.0B | ||
| Q3 25 | $689.9M | $740.3M | ||
| Q2 25 | $652.8M | $851.8M | ||
| Q1 25 | $580.7M | $710.6M | ||
| Q4 24 | $517.6M | $591.1M | ||
| Q3 24 | $442.3M | $680.6M | ||
| Q2 24 | $375.7M | $740.4M | ||
| Q1 24 | $310.4M | $754.4M |
| Q4 25 | $954.3M | $1.4B | ||
| Q3 25 | $920.2M | $1.4B | ||
| Q2 25 | $856.0M | $1.3B | ||
| Q1 25 | $794.3M | $1.3B | ||
| Q4 24 | $727.6M | $1.3B | ||
| Q3 24 | $660.9M | $1.3B | ||
| Q2 24 | $608.7M | $1.2B | ||
| Q1 24 | $561.4M | $1.2B |
| Q4 25 | $1.1B | $12.5B | ||
| Q3 25 | $1.1B | $12.2B | ||
| Q2 25 | $971.9M | $12.2B | ||
| Q1 25 | $908.9M | $11.7B | ||
| Q4 24 | $851.4M | $11.5B | ||
| Q3 24 | $772.0M | $11.5B | ||
| Q2 24 | $706.4M | $11.3B | ||
| Q1 24 | $646.7M | $11.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $217.7M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $199.3M |
| 自由现金流率自由现金流/营收 | 29.4% | 108.1% |
| 资本支出强度资本支出/营收 | 0.0% | 10.0% |
| 现金转化率经营现金流/净利润 | 0.85× | 3.90× |
| 过去12个月自由现金流最近4个季度 | — | $345.4M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $217.7M | ||
| Q3 25 | $32.4M | $39.5M | ||
| Q2 25 | $71.3M | $35.9M | ||
| Q1 25 | $60.0M | $83.1M | ||
| Q4 24 | $70.9M | $252.5M | ||
| Q3 24 | $72.9M | $58.1M | ||
| Q2 24 | $64.1M | $95.1M | ||
| Q1 24 | $31.9M | $61.0M |
| Q4 25 | $44.9M | $199.3M | ||
| Q3 25 | — | $35.5M | ||
| Q2 25 | $71.3M | $31.8M | ||
| Q1 25 | — | $78.7M | ||
| Q4 24 | $70.8M | $231.2M | ||
| Q3 24 | $72.6M | $51.8M | ||
| Q2 24 | $64.1M | $90.4M | ||
| Q1 24 | $31.7M | $54.8M |
| Q4 25 | 29.4% | 108.1% | ||
| Q3 25 | — | 19.1% | ||
| Q2 25 | 48.6% | 17.4% | ||
| Q1 25 | — | 44.1% | ||
| Q4 24 | 49.9% | 126.5% | ||
| Q3 24 | 56.4% | 29.6% | ||
| Q2 24 | 52.3% | 50.3% | ||
| Q1 24 | 32.2% | 31.4% |
| Q4 25 | 0.0% | 10.0% | ||
| Q3 25 | 0.0% | 2.1% | ||
| Q2 25 | 0.0% | 2.3% | ||
| Q1 25 | 0.0% | 2.4% | ||
| Q4 24 | 0.1% | 11.7% | ||
| Q3 24 | 0.2% | 3.6% | ||
| Q2 24 | 0.0% | 2.6% | ||
| Q1 24 | 0.2% | 3.5% |
| Q4 25 | 0.85× | 3.90× | ||
| Q3 25 | 0.61× | 0.76× | ||
| Q2 25 | 1.37× | 0.69× | ||
| Q1 25 | 1.06× | 1.82× | ||
| Q4 24 | 1.27× | 5.02× | ||
| Q3 24 | 1.66× | 1.24× | ||
| Q2 24 | 1.57× | 1.86× | ||
| Q1 24 | 1.37× | 1.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
OFG
暂无分部数据
